Results presented at the 63rd Annual American Society of Hematology Meeting showed that using polatuzumab vedotin instead of vincristine in R-CHOP improved progression-free survival in patients with ...
A review of treatment options in diffuse large B-cell lymphoma (DLBCL) addresses common subtypes and patient response to standard of care. Diffuse large B-cell lymphoma (DLBCL) is an aggressive type ...
The combination of Epkinly and R-mini-CHOP showed a 93% ORR and 86% CR rate in elderly DLBCL patients. At two years, 79% of patients remained in complete response, with a 76% progression-free survival ...
Pivotal studies testing new options in previously untreated double-expressor (MYC/BCL2) diffuse large B-cell lymphoma (DLBCL) yielded differing results, according to findings presented at the recent ...
Association of liposomal pegylated doxorubicine, fludarabine and cyclophosphamide as first line treatment in disseminated small B-cell lymphoma in adult patients ...
A Comparison of Logistic Regression Against Machine Learning Algorithms for Gastric Cancer Risk Prediction Within Real-World Clinical Data Streams We developed a predictive model (Tolerability of ...
—In a Danish registry study, patients with DLBCL who received R-CHOP-like therapies had an increased risk of infections, autoimmune conditions, and immune deficiencies compared with a matched ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results